CLINICAL TRIAL: EXENATIDE AND BODY WEIGHT IN OBESE NON-DIABETIC WOMEN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将考察埃塞那肽对中度肥胖、血糖平衡正常或血糖平衡受损但没有明显糖尿病的女性的体重、能量消耗、饱腹感、睡眠和代谢参数的影响。这是一项随机、双盲、交叉研究，受试者将接受为期16周的艾塞那肽或安慰剂治疗，两个疗程之间有2周的冲洗期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will examine the effect of exenatide on weight, energy expenditure, satiety, sleep and metabolic parameters in moderately obese women with normal glucose homeostasis or with impaired glucose homeostasis but not frank diabetes mellitus. This is a randomized, double blind, crossover study in which subjects will receive exenatide or placebo for 16 weeks with a 2-week washout period between treatment periods.